Obesity 2019: More Slices of Pie

The future market for treatments in obesity is certain to be more fragmented than it is now.  There will be more different types of treatments offered by drug companies, device companies, surgical procedures, and other options.

Recent market developments in the field of obesity have principally centered around the mixed signals put out by the FDA on obesity drugs.  Safety issues were responsible for major drugs by Arena Pharmaceuticals (Lorcaserin), Vivus (QNEXA) and Orexigen (Contrave) hitting roadblocks by the FDA indicating that the drugs in their current form would not be approved.  The FDA and the companies have moved rapidly since then toward developments encouraging investors that the companies' drugs may indeed reach the market in the not-too-distant future.

Whether it is these drugs, or others, it is clear that the market for obesity treatments will be represened by a significant number of drugs as well as devices over the next few years, yielding the following expected picture of the market in 2019:

 

Worldwide Obesity Drug & Device Treatment Market by Major Type

 

Source: MedMarket Diligence, LLC; Report #S835.

Posted via email from medmarket's posterous